Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 9/20 | 0.52 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7331231 | 0.84 | AVPR1A (0.53) | AVPR1AAVPR2 | |
| SCHEMBL7333960 | 0.83 | AVPR1A (0.51) | AVPR1AAVPR2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL7340479 | 0.82 | AVPR1A (0.74) | AVPR1AAVPR2 | |
| SCHEMBL7338976 | 0.75 | AVPR1A (0.51) | AVPR1AAVPR2ALDH1A1HPGDBCHE | |
| SCHEMBL7330985 | 0.75 | AVPR1A (0.51) | AVPR1AAVPR2HPGD | |
| SCHEMBL8318427 | 0.74 | AVPR1A (0.52) | AVPR1AAVPR2 | |
| SCHEMBL8317244 | 0.74 | AVPR1A (0.52) | AVPR1AAVPR2 | |
| SCHEMBL8314290 | 0.74 | AVPR1A (0.54) | AVPR1AAVPR2 | |
| SCHEMBL8319414 | 0.74 | AVPR1A (0.54) | AVPR1AAVPR2 | |
| SCHEMBL8318009 | 0.74 | AVPR1A (0.65) | AVPR1AAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5968930-A | FOR TREATMENT AND/OR PREVENTION OF HYPERTENSION, CARDIAC INSUFFICIENCY, CORONARY VASOSPASM, CARDIAC ISCHEMIA, RENAL VASOSPASM, LIVER CIRRHOSIS, CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME, BRAIN EDEMA, CEREBRAL ISCHEMIA | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5968937-A | FOR TREATMENT AND/OR PREVENTION OF HYPERTENSION, CARDIAC INSUFFICIENCY, CORONARY VASOSPASM, CARDIAC ISCHEMIA, RENAL VASOSPASM, LIVER CIRRHOSIS, CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME, BRAIN EDEMA, CEREBRAL ISCHEMIA | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0636625-B1 | Tricyclic diazepines vasopressin and oxytocin antagonists | AMERICAN CYANAMID CO (US) | 1999-01-27 | — | — | EP | disclosed |
| US-5624923-A | UROGENITAL AND CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| US-5516774-A | TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0636625-A2 | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-02-01 | — | — | EP | disclosed |